Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, ...
With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to ...
Garg, recently named to BioSpace’s 40 Under 40, proved her mettle managing one of the toughest partnerships out there: the ...
Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...
Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...
CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...
Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.
While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.
In this episode presented by PII, BioSpace’s head of insights discusses how China, historically focused on manufacturing, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback